 |
 Video: What is a Stock Split?
|
|
|
| Amicus Therapeutics is a biotechnology company focused on the discovering, developing, and delivering medicines for diseases. Co.'s Commercial Product and Product Candidates include Galafold® (Migalastat HCl), which is for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; Enzyme Replacement Therapy for Pompe disease; and Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder, which is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. According to our Amicus Therapeutics stock split history records, Amicus Therapeutics has had 0 splits. | |
|
Amicus Therapeutics (FOLD) has 0 splits in our Amicus Therapeutics stock split history database.
Looking at the Amicus Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Amicus Therapeutics shares, starting with a $10,000 purchase of FOLD, presented on a split-history-adjusted basis factoring in the complete Amicus Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/28/2011 |
|
| End date: |
02/25/2021 |
|
| Start price/share: |
$6.13 |
|
| End price/share: |
$11.92 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
94.45% |
|
| Average Annual Total Return: |
6.88% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$19,452.01 |
|
| Years: |
10.00 |
|
|
|
|
|
